Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells: MENTALO Study
Centre Hospitalier Universitaire de Saint Etienne
40 participants
May 25, 2022
INTERVENTIONAL
Conditions
Summary
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of consolidation, to maintain a durable response. In this situation, allograft with hematopoietic stem cells donor aims at producing Graft-versus-Tumor effect, by producing a new immune system, reproducing anti-tumoral immunity. However, all hemopathies do not have the same sensibility. Nowadays, mechanisms underlying this phenomenon remain poorly understood. Indeed, few data precisely document the expression of immunological checkpoints and other biomarkers in the context of allogeneic HSC transplantation, particularly their impact on post-transplant outcome.
Eligibility
Inclusion Criteria4
- Adult patient, over 18 years of age, suffering from a malignant hemopathy (without exception),
- Patient for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated,
- Signed informed consent,
- Patient covered by a social security scheme.
Exclusion Criteria3
- Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical transplant,
- Allogeneic transplant with post-transplant cyclophosphamide treatment,
- Allograft with sequential conditioning.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL: * Samples before the allograft, * Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days, * Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04517656